BioLife Solutions (BLFS) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

BLFS Stock Forecast

BioLife Solutions stock forecast is as follows: an average price target of $30.00 (represents a 8.81% upside from BLFS’s last price of $27.57) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.

BLFS Price Target

The average price target for BioLife Solutions (BLFS) is $30.00 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $30.00 to $30.00. This represents a potential 8.81% upside from BLFS's last price of $27.57.

BLFS Analyst Ratings

Buy

According to 7 Wall Street analysts, BioLife Solutions's rating consensus is 'Buy'. The analyst rating breakdown for BLFS stock is 0 'Strong Buy' (0.00%), 7 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

BioLife Solutions Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Nov 15, 2024	Jacob Johnson	Stephens	$30.00	$21.57	39.05%	8.81%
Aug 12, 2024	Matt Hewitt	Craig-Hallum	$30.00	$25.25	18.81%	8.81%
Apr 04, 2024	Matthew Stanton	Jefferies	$22.00	$17.32	27.02%	-20.20%

The latest BioLife Solutions stock forecast, released on Nov 15, 2024 by Jacob Johnson from Stephens, set a price target of $30.00, which represents a 39.05% increase from the stock price at the time of the forecast ($21.57), and a 8.81% increase from BLFS last price ($27.57).

BioLife Solutions Price Target by Period

	1M	3M	12M
# Anlaysts	-	1	3
Avg Price Target	-	$30.00	$27.33
Last Closing Price	$27.57	$27.57	$27.57
Upside/Downside	-100.00%	8.81%	-0.87%

In the current month, the average price target of BioLife Solutions stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to BioLife Solutions's last price of $27.57. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Nov 15, 2024	Stephens	Overweight	Overweight	Hold
Nov 13, 2024	Cowen & Co.	Buy	Buy	Hold
Sep 30, 2024	H.C. Wainwright		Buy	Initialise
Aug 12, 2024	Craig-Hallum	Buy	Buy	Hold
Jul 17, 2024	Cowen & Co.	Buy	Buy	Hold
May 13, 2024	Benchmark		Buy	Upgrade
Apr 04, 2024	Jefferies		Buy	Initialise
Apr 25, 2022	Oppenheimer		Outperform	Upgrade

BioLife Solutions's last stock rating was published by Stephens on Nov 15, 2024. The company gave BLFS a "Overweight" rating, the same as its previous rate.

BioLife Solutions Financial Forecast

BioLife Solutions Revenue Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$32.73M	$33.33M	$39.51M	$37.70M	$44.26M	$40.75M	$40.53M	$36.22M	$37.30M	$33.80M	$31.20M	$16.85M	$14.73M	$11.28M
Avg Forecast	$49.26M	$47.44M	$43.79M	$41.96M	$37.57M	$36.17M	$34.51M	$32.61M	$27.10M	$26.63M	$24.50M	$22.65M	$22.03M	$25.54M	$23.95M	$26.01M	$33.40M	$33.01M	$43.63M	$42.94M	$43.40M	$42.06M	$39.17M	$38.21M	$35.81M	$31.59M	$27.58M	$16.05M	$13.54M	$10.78M
High Forecast	$53.43M	$51.45M	$47.49M	$45.51M	$40.75M	$39.23M	$37.43M	$35.37M	$29.39M	$28.88M	$26.57M	$23.53M	$23.09M	$25.59M	$23.95M	$26.01M	$36.22M	$33.01M	$47.32M	$46.57M	$47.07M	$42.06M	$39.17M	$38.21M	$35.81M	$31.59M	$27.58M	$16.05M	$13.54M	$10.78M
Low Forecast	$41.38M	$39.85M	$36.78M	$35.25M	$31.56M	$30.38M	$28.99M	$27.39M	$22.77M	$22.37M	$20.58M	$21.77M	$19.79M	$25.48M	$23.95M	$26.01M	$28.06M	$33.01M	$36.66M	$36.07M	$36.46M	$42.06M	$39.17M	$38.21M	$35.81M	$31.59M	$27.58M	$16.05M	$13.54M	$10.78M
# Analysts	1	1	1	1	1	1	1	1	1	1	1	3	7	3	2	2	4	2	2	2	1	1	1	1	2	2	2	2	11	15
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.98%	1.01%	0.91%	0.88%	1.02%	0.97%	1.03%	0.95%	1.04%	1.07%	1.13%	1.05%	1.09%	1.05%

BioLife Solutions's average Quarter revenue forecast for Mar 24 based on 2 analysts is $26.01M, with a low forecast of $26.01M, and a high forecast of $26.01M. BLFS's average Quarter revenue forecast represents a -20.55% decrease compared to the company's last Quarter revenue of $32.73M (Dec 23).

BioLife Solutions EBITDA Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	1	1	1	1	1	1	1	1	1	1	1	3	7	3	2	2	4	2	2	2	1	1	1	1	2	2	2	2	11	15
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-13.15M	$-11.36M	$-15.28M	$-11.03M	$-8.32M	$-3.10M	$-4.27M	$-9.77M	$-9.14M	$-13.54M	$2.42M	$1.86M	$-2.61M	$129.00K
Avg Forecast	$-6.09M	$-5.87M	$-5.42M	$-5.19M	$-4.65M	$-4.47M	$-4.27M	$-4.03M	$-3.35M	$-3.29M	$-3.03M	$-2.80M	$-2.73M	$-3.16M	$-2.96M	$-4.50M	$-4.13M	$-4.08M	$-5.40M	$-4.81M	$-11.63M	$-6.09M	$-5.67M	$-4.37M	$-5.19M	$-4.58M	$-3.99M	$740.00K	$-1.96M	$-1.56M
High Forecast	$-5.12M	$-4.93M	$-4.55M	$-4.36M	$-3.90M	$-3.76M	$-3.59M	$-3.39M	$-2.82M	$-2.77M	$-2.55M	$-2.69M	$-2.45M	$-3.15M	$-2.96M	$-3.60M	$-3.47M	$-4.08M	$-4.53M	$-3.85M	$-9.30M	$-6.09M	$-5.67M	$-3.50M	$-5.19M	$-4.58M	$-3.99M	$888.00K	$-1.96M	$-1.56M
Low Forecast	$-6.61M	$-6.36M	$-5.87M	$-5.63M	$-5.04M	$-4.85M	$-4.63M	$-4.37M	$-3.64M	$-3.57M	$-3.29M	$-2.91M	$-2.86M	$-3.17M	$-2.96M	$-5.40M	$-4.48M	$-4.08M	$-5.85M	$-5.77M	$-13.96M	$-6.09M	$-5.67M	$-5.25M	$-5.19M	$-4.58M	$-3.99M	$592.00K	$-1.96M	$-1.56M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.18%	2.78%	2.83%	2.29%	0.72%	0.51%	0.75%	2.23%	1.76%	2.96%	-0.61%	2.52%	1.33%	-0.08%

2 analysts predict BLFS's average Quarter EBITDA for Sep 21 to be $-4.58M, with a high of $-4.58M and a low of $-4.58M. This is -288.70% lower than BioLife Solutions's previous annual EBITDA (Jun 21) of $2.42M.

BioLife Solutions Net Income Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	1	1	1	1	1	1	1	1	1	1	1	3	7	3	2	2	4	2	2	2	1	1	1	1	2	2	2	2	11	15
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-13.47M	$-29.13M	$-10.20M	$-13.71M	$-49.19M	$-9.96M	$-72.55M	$-7.07M	$-14.47M	$79.00K	$7.88M	$-1.12M	$-2.13M	$-1.13M
Avg Forecast	-	-	-	-	$1.85M	$923.51K	$923.51K	$461.75K	$-1.62M	$-1.27M	$-1.96M	$-3.00M	$-3.81M	$-3.62M	$-6.39M	$-9.59M	$-15.78M	$-17.32M	$-9.70M	$-10.26M	$-13.29M	$-7.59M	$-9.61M	$-9.33M	$-7.75M	$-3.94M	$-1.90M	$-1.40M	$-747.57K	$-722.91K
High Forecast	-	-	-	-	$2.05M	$1.02M	$1.02M	$512.50K	$-1.28M	$-1.01M	$-1.55M	$-2.25M	$-952.37K	$-2.86M	$-5.06M	$-7.67M	$-12.50M	$-13.72M	$-7.68M	$-8.21M	$-10.64M	$-7.59M	$-9.61M	$-7.46M	$-7.75M	$-3.94M	$-1.90M	$-1.12M	$-747.57K	$-722.91K
Low Forecast	-	-	-	-	$1.46M	$731.48K	$731.48K	$365.74K	$-1.79M	$-1.41M	$-2.18M	$-3.75M	$-8.57M	$-4.01M	$-7.09M	$-11.51M	$-17.51M	$-19.22M	$-10.76M	$-12.31M	$-15.95M	$-7.59M	$-9.61M	$-11.19M	$-7.75M	$-3.94M	$-1.90M	$-1.68M	$-747.57K	$-722.91K
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.85%	1.68%	1.05%	1.34%	3.70%	1.31%	7.55%	0.76%	1.87%	-0.02%	-4.15%	0.80%	2.85%	1.57%

BioLife Solutions's average Quarter net income forecast for Dec 21 is $-7.75M, with a range of $-7.75M to $-7.75M. BLFS's average Quarter net income forecast represents a -9916.33% decrease compared to the company's last Quarter net income of $79.00K (Sep 21).

BioLife Solutions SG&A Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	1	1	1	1	1	1	1	1	1	1	1	3	7	3	2	2	4	2	2	2	1	1	1	1	2	2	2	2	11	15
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$17.51M	$19.77M	$21.72M	$21.31M	$18.56M	$16.86M	$16.77M	$16.09M	$15.17M	$14.15M	$10.29M	$6.85M	$6.57M	$5.09M
Avg Forecast	$23.08M	$22.23M	$20.52M	$19.66M	$17.60M	$16.95M	$16.17M	$15.28M	$12.70M	$12.48M	$11.48M	$10.61M	$10.32M	$11.97M	$11.22M	$21.84M	$15.65M	$15.47M	$20.45M	$23.36M	$13.93M	$19.71M	$18.35M	$21.23M	$16.78M	$14.80M	$12.92M	$8.56M	$6.35M	$5.05M
High Forecast	$25.03M	$24.11M	$22.25M	$21.32M	$19.09M	$18.38M	$17.54M	$16.57M	$13.77M	$13.53M	$12.45M	$11.02M	$10.82M	$11.99M	$11.22M	$26.21M	$16.97M	$15.47M	$22.17M	$28.03M	$16.72M	$19.71M	$18.35M	$25.48M	$16.78M	$14.80M	$12.92M	$10.28M	$6.35M	$5.05M
Low Forecast	$19.39M	$18.67M	$17.24M	$16.52M	$14.79M	$14.24M	$13.58M	$12.84M	$10.67M	$10.48M	$9.64M	$10.20M	$9.27M	$11.94M	$11.22M	$17.47M	$13.15M	$15.47M	$17.17M	$18.69M	$11.15M	$19.71M	$18.35M	$16.99M	$16.78M	$14.80M	$12.92M	$6.85M	$6.35M	$5.05M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.12%	1.28%	1.06%	0.91%	1.33%	0.86%	0.91%	0.76%	0.90%	0.96%	0.80%	0.80%	1.04%	1.01%

BioLife Solutions's average Quarter SG&A projection for Mar 24 is $21.84M, based on 2 Wall Street analysts, with a range of $17.47M to $26.21M. The forecast indicates a 24.75% rise compared to BLFS last annual SG&A of $17.51M (Dec 23).

BioLife Solutions EPS Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	1	1	1	1	1	1	1	1	1	1	1	3	7	3	2	2	4	2	2	2	1	1	1	1	2	2	2	2	11	15
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.00	$-0.67	$-0.00	$-0.32	$-1.15	$-0.23	$-1.71	$-0.17	$-0.35	-	$0.20	$-0.07	$-0.06	$-0.04
Avg Forecast	-	-	-	-	$0.04	$0.02	$0.02	$0.01	$-0.04	$-0.03	$-0.04	$-0.07	$-0.08	$-0.08	$-0.14	$-0.31	$-0.34	$-0.38	$-0.21	$-0.21	$-0.16	$-0.17	$-0.21	$-0.26	$-0.17	$-0.09	$-0.04	$-0.04	$-0.02	$-0.02
High Forecast	-	-	-	-	$0.04	$0.02	$0.02	$0.01	$-0.03	$-0.02	$-0.03	$-0.05	$-0.02	$-0.06	$-0.11	$-0.24	$-0.27	$-0.30	$-0.17	$-0.17	$-0.13	$-0.17	$-0.21	$-0.26	$-0.17	$-0.09	$-0.04	$-0.04	$-0.02	$-0.02
Low Forecast	-	-	-	-	$0.03	$0.02	$0.02	$0.01	$-0.04	$-0.03	$-0.05	$-0.08	$-0.19	$-0.09	$-0.15	$-0.34	$-0.38	$-0.42	$-0.23	$-0.24	$-0.18	$-0.17	$-0.21	$-0.26	$-0.17	$-0.09	$-0.04	$-0.04	$-0.02	$-0.02
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00%	1.79%	0.00%	1.50%	7.13%	1.39%	8.19%	0.65%	2.08%	-0.02%	-4.85%	1.89%	3.98%	2.42%

According to 2 Wall Street analysts, BioLife Solutions's projected average Quarter EPS for Dec 21 is $-0.17, with a low estimate of $-0.17 and a high estimate of $-0.17. This represents a -8972.11% decrease compared to BLFS previous annual EPS of - (Sep 21).

BioLife Solutions Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
AKYA	Akoya Biosciences	$2.54	$4.83	90.16%	Buy
TFX	Teleflex	$178.28	$254.50	42.75%	Buy
ANGO	AngioDynamics	$9.26	$13.00	40.39%	Buy
HAE	Haemonetics	$82.07	$107.00	30.38%	Buy
ATRC	AtriCure	$31.50	$39.67	25.94%	Buy
ATR	AptarGroup	$163.09	$200.00	22.63%	Buy
COO	Cooper Companies	$94.49	$115.00	21.71%	Buy
ALC	Alcon	$85.54	$104.00	21.58%	Buy
ICUI	ICU Medical	$157.17	$190.50	21.21%	Buy
WST	West Pharmaceutical Services	$334.26	$393.00	17.57%	Buy
BLFS	BioLife Solutions	$26.87	$30.00	11.65%	Buy
RMD	ResMed	$242.62	$233.50	-3.76%	Hold
KRMD	KORU Medical Systems	$4.12	$3.25	-21.12%	Buy

BLFS Forecast FAQ

Is BioLife Solutions a good buy?

Yes, according to 7 Wall Street analysts, BioLife Solutions (BLFS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 100.00% of BLFS's total ratings.

What is BLFS's price target?

BioLife Solutions (BLFS) average price target is $30 with a range of $30 to $30, implying a 8.81% from its last price of $27.57. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will BioLife Solutions stock go up soon?

According to Wall Street analysts' prediction for BLFS stock, the company can go up by 8.81% (from the last price of $27.57 to the average price target of $30), up by 8.81% based on the highest stock price target, and up by 8.81% based on the lowest stock price target.

Can BioLife Solutions stock reach $40?

BLFS's average twelve months analyst stock price target of $30 does not support the claim that BioLife Solutions can reach $40 in the near future.

What are BioLife Solutions's analysts' financial forecasts?

BioLife Solutions's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $140.86M (high $152.77M, low $118.33M), average EBITDA is $-17.422M (high $-14.635M, low $-18.895M), average net income is $4.16M (high $4.61M, low $3.29M), average SG&A $66M (high $71.58M, low $55.44M), and average EPS is $0.09 (high $0.0999, low $0.0713). BLFS's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $182.45M (high $197.88M, low $153.27M), average EBITDA is $-22.566M (high $-18.957M, low $-24.474M), average net income is $0 (high $0, low $0), average SG&A $85.49M (high $92.71M, low $71.81M), and average EPS is $0 (high $0, low $0).

Did the BLFS's actual financial results beat the analysts' financial forecasts?

Based on BioLife Solutions's last annual report (Dec 2023), the company's revenue was $143.27M, which missed the average analysts forecast of $152.99M by -6.35%. Apple's EBITDA was $-70.825M, beating the average prediction of $-18.419M by 284.52%. The company's net income was $-66.089M, beating the average estimation of $-53.049M by 24.58%. Apple's SG&A was $80.31M, beating the average forecast of $74.92M by 7.19%. Lastly, the company's EPS was $-0.0015, missing the average prediction of $-1.14 by -99.87%. In terms of the last quarterly report (Dec 2023), BioLife Solutions's revenue was $32.73M, missing the average analysts' forecast of $33.4M by -2.00%. The company's EBITDA was $-13.155M, beating the average prediction of $-4.131M by 218.46%. BioLife Solutions's net income was $-13.469M, missing the average estimation of $-15.777M by -14.63%. The company's SG&A was $17.51M, beating the average forecast of $15.65M by 11.87%. Lastly, the company's EPS was $-0.0003, missing the average prediction of $-0.342 by -99.91%